Omalizumab maintains a longer remission period than predicted: An observational study

Year 2021, Volume: 14 Issue: 3, 504 - 508, 15.12.2021

Belma Türsen Habibullah Aktaş

https://doi.org/10.26559/mersinsbd.1007723

Abstract

Objective: Omalizumab is a monoclonal anti-IgE antibody used in the treatment of chronic urticaria resistant to antihistamines. Its application every four weeks is recommended. Methods: The effects of age, gender, duration and severity of urticaria on the duration of remission achieved with omalizumab on the response of 15 patients with a diagnosis of chronic urticaria to subcutaneous omalizumab therapy were investiagted. Results: Remission was achieved for an average of 6.26±2.7 weeks in 8 female and 7 male patients with a mean age of 43.9±7.8 years. While age, gender, duration and severity of urticaria did not affect the remission period, it was observed that the remission period was short in patients with urticaria accompanied by asthma. Conclusion: Omalizumab provides a longer remission than the four-week duration of action.

Keywords

omalizumab, remission, urticaria

Omalizumab tahmin edilenden daha uzun remisyon sağlıyor: Gözlemsel bir çalışma

Abstract

Amaç: Omalizumab, antihistaminlere dirençli kronik ürtiker tedavisinde kullanılan monoklonal anti IgE antikorudur. Her dört haftada bir uygulama önerilmektedir.
Yöntem: Kronik ürtiker tanısıyla izlenen 15 hastanın subkutan omalizumab tedavisine yanıtı yaş, cinsiyet, ürtiker süresi ve şiddetinin omalizumab ile elde edilen remisyon süresine etkisi incelendi. Bulgular: Yaş ortalaması 43.9±7.8 olan 8 kadın 7 erkek hastada ortalama 6.26±2.7 hafta remisyon sağlandı. Yaş, cinsiyet, ürtiker süre ve şiddeti remisyon süresini etkilemezken, ürtikerine astım eşlik eden hastalarda remisyon süresinin kısa olduğu gözlendi. Sonuç: Omalizumab dört hafta olarak belirlenen etki süresinden daha uzun remisyon sağlamaktadır.

Keywords

omalizumab, ürtiker, remisyon

References

• 1. Goncü EK, Aktan S, Atakan N,et al. The Turkish guideline for the diagnosis and management of urticaria-2016. Turkderm - Arch Turk Dermatol Venerology, 2016;50:82-98.
• 2. Akyol A, Öktem A, Akay BN, et al. Omalizumab ve tedaviye dirençli kronik spontan ürtiker tedavisindeki yeri. Turkderm-Turk Arch Dermatol Venereology, 2015;49:180-3.
• 3. Neema S, Chatterjee M. Omalizumab for management of refractory urticaria: experience of a tertiary care centre in Eastern India. Indian J Dermatol, 2018;63(1):66–69.
• 4. Oblitas CM, Galeano-Valle F, Vela-De La Cruz L, et al. Omalizumab as a provoking factor for venous thromboembolism. Drug Target Insights. 2019; 13:1177392819861987. Published 2019 Jul 4.
• 5. Aguiar-Ricardo I, Nunes-Ferreira A, Roda Â, et al. Omalizumab induced Takotsubo syndrome: case report. Eur Heart J Case Rep, 2019;3(1):yty155. Published 2019 Jan 3.
• 6. Cildag S. Triggering atrial fibrillation after omalizumab injection in a patient with chronic spontaneous urticarial. A case report. Med Pharm Rep, 2019 Jan;92(1):91-93. doi: 10.15386/cjmed-1082. Epub 2019 Jan 15.
• 7. Ozbagcivan O, Akarsu S, Ilknur T,et al. Urticaria and angioedema as possible reactions of omalizumab. An Bras Dermatol, 2018;93(2):304–305. doi:10.1590/abd1806-4841.20187074
• 8. Ertaş R, Özyurt K, Yıldız S, et al. Adverse reaction to omalizumab in patients with chronic urticaria: flare up or ıneffectiveness? Iran J Allergy Asthma Immunol, 15(1):82-86.
• 9. Viswanathan RK, Moss MH, Mathur SK. Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria. Allergy Asthma Proc, 2013; 34(5):446-52.
• 10. Naaman S, Sussman G. Chronic idiopathic urticaria: treatment with omalizumab. Skin Therapy Lett, 2014;19(6):1–4.
• 11. Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol, 2016;137(2):474–481. doi:10.1016/j.jaci.2015.08.023
• 12. Silva PM, Costa AC, Mendes A, et al. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria. Allergol Immunopathol (Madr), 2015;43(2):168–173. doi:10.1016/j.aller.2013.11.007
• 13. Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria. Ann Allergy Asthma Immunol, 2015;115(2):126–129.
• 14. Song CH, Stern S, Giruparajah M,et al. Eficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol, 2013 Feb; 110(2):113-7.
• 15. Uysal P, Eller E, Mortz CG,et al. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized. J Allergy Clin Immunol, 2014;133(3):914–5.e2. doi:10.1016/j.jaci.2013.10.015